| P2093 | author name string | Joseph T Coyle | |
| P2860 | cites work | Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia | Q24308818 |
| | Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia | Q24531526 |
| | Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series | Q24532007 |
| | Early-stage visual processing and cortical amplification deficits in schizophrenia | Q24536566 |
| | A decrease of reelin expression as a putative vulnerability factor in schizophrenia | Q24657918 |
| | Hypoxic-ischemia-related fetal/neonatal complications and risk of schizophrenia and other nonaffective psychoses: a 19-year longitudinal study | Q28144525 |
| | D-serine added to clozapine for the treatment of schizophrenia | Q28146259 |
| | Genes for schizophrenia? Recent findings and their pathophysiological implications | Q28207952 |
| | Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies | Q28215775 |
| | Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia | Q28239090 |
| | D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia | Q28240880 |
| | Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia | Q28250711 |
| | Effectiveness of antipsychotic drugs in patients with chronic schizophrenia | Q28273164 |
| | Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies | Q28304567 |
| | Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia | Q28568230 |
| | Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence | Q29618819 |
| | Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses | Q29618915 |
| | Recent advances in the phencyclidine model of schizophrenia | Q29618917 |
| | A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors | Q48247770 |
| | Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects | Q48855793 |
| | Functional comparison of D-serine and glycine in rodents: the effect on cloned NMDA receptors and the extracellular concentration. | Q49047741 |
| | NMDA-dependent modulation of CA1 local circuit inhibition. | Q49058538 |
| | Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities? | Q49093044 |
| | D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes | Q49095632 |
| | M50 sensory gating predicts negative symptoms in schizophrenia | Q49143378 |
| | A single dominant gene can account for eye tracking dysfunctions and schizophrenia in offspring of discordant twins. | Q50800943 |
| | Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder. | Q51034630 |
| | Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection | Q51116341 |
| | Effect of Phencyclidine in Chronic Schizophrenics | Q51215455 |
| | Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. | Q51370914 |
| | Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. | Q51375205 |
| | Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. | Q51481467 |
| | Functional significance of long-term potentiation for sequence learning and prediction. | Q52048346 |
| | Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. | Q52057976 |
| | Study of a new schizophrenomimetic drug; sernyl. | Q52771570 |
| | D-cycloserine added to clozapine for patients with schizophrenia | Q57131290 |
| | Findings in an independent sample support an association between bipolar affective disorder and the G72/G30 locus on chromosome 13q33 | Q57405103 |
| | Support for involvement of neuregulin 1 in schizophrenia pathophysiology | Q59192038 |
| | Transmission disequilibrium and haplotype analyses of the G72/G30 locus: Suggestive linkage to schizophrenia in Palestinian Arabs living in the North of Israel | Q60719829 |
| | [3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics | Q70158501 |
| | Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial | Q71607775 |
| | Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia | Q71933595 |
| | Dopamine receptors, neuroleptics, and schizophrenia | Q72461206 |
| | N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells | Q73456893 |
| | Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons | Q73689679 |
| | Placebo-controlled trial of glycine added to clozapine in schizophrenia | Q73719184 |
| | The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia | Q73967057 |
| | Impaired P3 generation reflects high-level and progressive neurocognitive dysfunction in schizophrenia | Q76392641 |
| | A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia | Q77805002 |
| | Localized volume reduction in prefrontal, temporolimbic, and paralimbic regions in schizophrenia: an MRI parcellation study | Q80822000 |
| | Neuroimaging studies of the hippocampus in schizophrenia | Q30666577 |
| | A review of diffusion tensor imaging studies in schizophrenia | Q30994764 |
| | Effects of a novel uncompetitive NMDA receptor antagonist, MRZ 2/579 on ethanol self-administration and ethanol withdrawal seizures in the rat. | Q31925767 |
| | Significant interaction between clozapine and cocaine in cocaine addicts | Q33145592 |
| | The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia | Q33693516 |
| | Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey | Q33827207 |
| | Finding schizophrenia genes | Q33831956 |
| | Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia | Q33941953 |
| | GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder | Q33948632 |
| | The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner | Q33951128 |
| | Atypical antipsychotics: mechanism of action. | Q33957716 |
| | Ionotropic glutamate receptors as therapeutic targets in schizophrenia | Q33966231 |
| | Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. | Q33966453 |
| | LTP may trigger addiction | Q33976331 |
| | Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients | Q33987618 |
| | D-serine added to antipsychotics for the treatment of schizophrenia | Q34068005 |
| | The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans | Q34087393 |
| | Effects of ketamine in normal and schizophrenic volunteers | Q34091266 |
| | Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden | Q34201663 |
| | Association of G72/G30 with schizophrenia in the Chinese population | Q34326702 |
| | The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia | Q34327773 |
| | Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder | Q34331509 |
| | Is the G72/G30 locus associated with schizophrenia? single nucleotide polymorphisms, haplotypes, and gene expression analysis | Q34335482 |
| | Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear | Q34364137 |
| | How does drug and alcohol misuse develop among people with psychotic illness? A literature review | Q34388833 |
| | The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism | Q34428531 |
| | Is there a common molecular pathway for addiction? | Q34463226 |
| | A meta-analysis of the efficacy of second-generation antipsychotics | Q34534321 |
| | Substance misuse in patients with schizophrenia: epidemiology and management | Q34585142 |
| | Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia | Q34756417 |
| | Neuregulins: functions, forms, and signaling strategies | Q35089314 |
| | N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability | Q35153745 |
| | The neurobiology of opiate tolerance, dependence and sensitization: mechanisms of NMDA receptor-dependent synaptic plasticity | Q35164063 |
| | NMDA receptors in alcoholism | Q35616724 |
| | Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction | Q35810087 |
| | The N-methyl D-aspartate receptor glycine site and D-serine metabolism: an evolutionary perspective | Q35861036 |
| | Effects of D-cycloserine on negative symptoms in schizophrenia | Q35913587 |
| | A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia | Q36070114 |
| | Acamprosate: a review of its use in the maintenance of abstinence in patients with alcohol dependence | Q36133836 |
| | Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia | Q37698891 |
| | Ketamine: an update on the first twenty-five years of clinical experience | Q38618138 |
| | Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo | Q40408851 |
| | Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action | Q40531131 |
| | Decoding neuronal firing and modelling neural networks | Q40617076 |
| | Evidence for abnormal cortical functional connectivity during working memory in schizophrenia | Q40678204 |
| | Abnormal excitatory neurotransmitter metabolism in schizophrenic brains | Q41670269 |
| | Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia | Q41695764 |
| | A comparison of smoking behaviours between patients treated with clozapine and depot neuroleptics | Q43734438 |
| | Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation | Q43762654 |
| | Increased cortical kynurenate content in schizophrenia | Q43766055 |
| | Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia | Q43783037 |
| | Concomitant clozapine reduces smoking in patients treated with risperidone | Q43852515 |
| | Adjunctive high-dose glycine in the treatment of schizophrenia | Q43863838 |
| | Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia | Q43899475 |
| | NMDA receptor antagonists disinhibit rat posterior cingulate and retrosplenial cortices: a potential mechanism of neurotoxicity. | Q43954489 |
| | Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia | Q44129418 |
| | Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone | Q44264708 |
| | Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). | Q44268852 |
| | Comparative genome- and proteome analysis of cerebral cortex from MK-801-treated rats | Q44291905 |
| | Local acamprosate modulates dopamine release in the rat nucleus accumbens through NMDA receptors: an in vivo microdialysis study. | Q44321771 |
| | The NMDA receptor channel blocker memantine and opioid receptor antagonist naltrexone inhibit the saccharin deprivation effect in rats | Q44346065 |
| | Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex | Q44347334 |
| | The effect of acamprosate on the development of morphine-induced behavioral sensitization in rats | Q44499626 |
| | Memantine presents different effects from MK-801 in motivational and physical signs of morphine withdrawal. | Q44567442 |
| | Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia: a proton magnetic resonance spectroscopy study | Q44597810 |
| | Effect of systemic administration of D-serine on the levels of D- and L-serine in several brain areas and periphery of rat. | Q44974843 |
| | Endogenous kynurenic acid disrupts prepulse inhibition | Q45019400 |
| | NAAG reduces NMDA receptor current in CA1 hippocampal pyramidal neurons of acute slices and dissociated neurons | Q45049155 |
| | Clozapine reduces alcohol drinking in Syrian golden hamsters | Q45080179 |
| | A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients | Q45122746 |
| | Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine | Q45262973 |
| | Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex. | Q46497163 |
| | Effect of catechol-O-methyltransferase val158met genotype on attentional control. | Q46497177 |
| | Cerebral ventricular change over the first 10 years after the onset of schizophrenia | Q47198232 |
| | Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain | Q47378030 |
| | Polymorphisms in the 13q33.2 gene G72/G30 are associated with childhood-onset schizophrenia and psychosis not otherwise specified | Q47664212 |
| | Comparison of progressive cortical gray matter loss in childhood-onset schizophrenia with that in childhood-onset atypical psychoses | Q48100357 |
| | MRI assessment of gray and white matter distribution in Brodmann's areas of the cortex in patients with schizophrenia with good and poor outcomes | Q48135275 |
| | Reduced hippocampal N-acetylaspartate without volume loss in schizophrenia | Q48165321 |
| P433 | issue | 3-4 | |
| P921 | main subject | schizophrenia | Q41112 |
| P1104 | number of pages | 13 | |
| P304 | page(s) | 221-233 | |
| P577 | publication date | 2006-12-01 | |
| P1433 | published in | Neurotoxicity Research | Q15764278 |
| P1476 | title | Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms | |
| P478 | volume | 10 | |